NHD Global
Growth Hormone & IGF · GHRF analogue research
Scientific Product Dossier
Tesamorelin is a growth hormone-releasing factor analogue that stimulates pituitary growth hormone secretion and raises IGF-1. An FDA-approved branded tesamorelin medicine has a narrow indication for reducing excess abdominal fat in adults with HIV and lipodystrophy and is explicitly not indicated for weight-loss management. Catalog research material is not that approved drug.
Shared values below are consolidated from the current catalog record. They are not independent verification or lot results; the current product specification and lot COA control.
Product identity
Literature reference parameters
Identity safeguard Reference identifiers above describe the literature compound record. The supplied form, formula, molecular weight, purity and storage conditions must be verified against the product-specific specification and lot COA.
A target-to-pathway view grounded in the linked research records.
Reported research findings
Reported outcomes are paired with their experimental model and evidence boundary.
Randomized controlled research reported significant reductions in visceral adipose tissue and improvements in selected body-composition measures in the defined HIV-lipodystrophy population.
Population- and indication-specific evidence; it cannot support general weight-loss, bodybuilding or anti-aging claims.
Read the primary studyFDA labeling authorizes a specific tesamorelin drug product for reducing excess abdominal fat in adults with HIV and lipodystrophy and states it is not indicated for weight-loss management.
Approval does not apply to third-party catalog research material.
Read the primary studyFDA labeling warns that the regulated product increases IGF-1 and may cause glucose intolerance or diabetes.
The approved indication is not general weight management, and the label does not establish safety or identity for research catalog material.
Read the primary studyCatalog options
Pack-level catalog data; lot-level controls remain document-specific.
Single-component peptide · 2 mg/vial nominal · 10-vial pack · supplied form and release limits controlled by lot specification.
Request by lot: CoA, HPLC purity and MS identity
Single-component peptide · 5 mg/vial nominal · 10-vial pack · supplied form and release limits controlled by lot specification.
Request by lot: CoA, HPLC purity and MS identity
Single-component peptide · 10 mg/vial nominal · 10-vial pack · supplied form and release limits controlled by lot specification.
Request by lot: CoA, HPLC purity and MS identity
Single-component peptide · 20 mg/vial nominal · 10-vial pack · supplied form and release limits controlled by lot specification.
Request by lot: CoA, HPLC purity and MS identity
Document availability is stated honestly and can vary by catalog variant or lot.
Analytical interpretation
Use the source-reviewed guide to separate chromatographic area purity, quantitative assay, LC-MS identity, composition and stability evidence before comparing variants or requesting a lot record.
Open the Quality & Documentation HubHPLC area ≠ assayA dominant peak does not establish target mass fraction.
Intact mass ≠ full sequenceIdentity strength depends on resolution and orthogonal evidence.
Counterions affect contentWater, salt form and solvents change the as-is composition.
Storage needs a data basisShipping practice is not the same as stability evidence.
Evidence map
Published studies and regulatory records, not customer testimonials or usage guidance.
Controlled clinical research in a defined adult HIV-lipodystrophy population; not general obesity research.
View primary recordAuthoritative source for the narrow indication and the explicit statement that the approved product is not for weight-loss management.
View primary recordThird-party publications selected for direct relevance.
Falutz J, et al. Journal of Acquired Immune Deficiency Syndromes. PMID 20101189 · DOI 10.1097/QAI.0b013e3181cbdaff
U.S. Food and Drug Administration. 2025 labeling record for BLA 022505.
Concise answers for researchers comparing identity, evidence and catalog variants.
Tesamorelin is a growth hormone-releasing factor analogue that stimulates pituitary growth hormone secretion and downstream IGF-1.
No. The FDA-approved branded medicine has a narrow indication for reducing excess abdominal fat in adults with HIV and lipodystrophy and is not indicated for weight-loss management.
No. This is research, development and manufacturing material and must not be represented as the regulated branded drug.
A lot-specific COA, product specification sheet and analytical method summary can be requested where applicable.
Store at -20 °C, protected from light and moisture. After reconstitution, aliquot and avoid repeated freeze-thaw cycles. Confirm the applicable storage statement on the product-specific specification and lot documentation.
Knowledge center
Owned educational content connected to this family.
An evidence-led review of tesamorelin trials in adults with HIV-associated abdominal fat accumulation, including endpoints, limits and FDA-labeled context.
Updated August 28, 2026
A clear comparison between a tesamorelin research material and the FDA-approved EGRIFTA WR finished drug, focusing on formulation, documentation and evidence transfer.
Updated August 28, 2026Knowledge tools
Move from this dossier into canonical evidence maps, verified status records, analytical interpretation and laboratory calculations.
Published-study results are tied to the linked records and kept separate from catalog-lot claims. Imported purity, storage and document-availability templates have been removed pending product- and lot-specific confirmation.
Technical procurement
Selected: TSM2 · 2 mg × 10 vials
Tell us what you need. Your enquiry will be routed to the appropriate contact for catalog numbers, availability and quotation details.
